arrow
M

Mauro Krampera

university of verona
H指数:61
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes and Treatment-Related Risks of Outpatient Versus Inpatient Management in Patients Receiving Hypomethylating Agent–Venetoclax Therapy: A Multicenter Retrospective Study

门诊与住院管理模式在低甲基化制剂-维奈克拉治疗患者中的结局及治疗相关风险:一项多中心回顾性研究

2026-09-250
PRE
Outcomes of CAR T-Cell Therapy in Transformed Indolent Non-Hodgkin Lymphomas and de novo DLBCL: a comparative analysis from the Italian CAR T-SIE study

CAR T细胞疗法在转化型惰性非霍奇金淋巴瘤和原发型DLBCL中的疗效:来自意大利CAR T-SIE研究的比较分析

2026-06-130
PRE
Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front-line hypomethylating agents and venetoclax: A retrospective Italian study

原发性和继发性急性髓系白血病患者接受一线低甲基化药物和维奈克拉治疗后的预后:一项意大利回顾性研究

2026-05-280
OAAI
Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study

occult 乙型肝炎病毒感染状态与抗CD19 CAR-T细胞疗法治疗淋巴瘤的疗效受损无关,并显示出独特的免疫毒性特征:CART-SIE研究的结果

2026-05-210
OAAI
Polatuzumab vedotin–containing regimens as bridge to CART: analysis from the CART-SIE study

Polatuzumab vedotin-含方案作为桥接CART:CART-SIE研究分析

2026-05-070
OA
Autologous Stem Cell Transplantation in HIV-Positive and HIV-Negative Patients with Lymphoma: A Propensity Score-Matched Comparative Analysis

自体干细胞移植在HIV阳性与HIV阴性淋巴瘤患者中的应用:一项倾向性评分匹配的对比分析

Cancers
IF4.4
2026-02-110
OAAI
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE-FIRST study

老年套细胞淋巴瘤患者中,首次进展时间和体能状态的作用:ELDERLY MANTLE-FIRST研究的结果

2025-12-010
OAAI
Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions

外源性移植MSCs的命运与功能:当前见解与未来方向

2025-11-150
PRE
Developing a 3D Model Culture of an EBV+/CD30+ B-Anaplastic Large Cell Lymphoma Cell Line to Assay Brentuximab Vedotin Treatment

开发一种EBV+/CD30+ B-间变性大细胞淋巴瘤细胞系的3D模型培养,以检测 Brentuximab Vedotin 治疗。

2025-11-100
OAAI
Ten-year trend of rituximab use for hematological malignancies: a multiregional real-world study using the Italian VALORE distributed database network

利妥昔单抗用于血液系统恶性肿瘤的十年趋势:一项基于意大利VALORE分布式数据库网络的跨区域真实世界研究

2025-11-050
PRE
CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study
2025-11-011
OA
Risk Factors for Persisting SARS-CoV-2 Infection in Patients with B-Cell Malignancies in the Omicron Era: A Multicenter Cohort Study

奥密克戎时代B细胞恶性肿瘤患者持续性SARS-CoV-2感染的危险因素:一项多中心队列研究

2025-09-080
OAAI
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study

PNH克隆在Ph阴性骨髓增殖性肿瘤中的流行病学研究:一项意大利多中心研究

2025-08-220
OAAI
Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis

CAR T细胞疗法在高等级B细胞淋巴瘤中的疗效与弥漫大B细胞淋巴瘤的比较:一项加权比较分析

2025-08-070
OAAI